首页 > 最新文献

TouchREVIEWS in endocrinology最新文献

英文 中文
Seliciclib: A New Treatment for Cushing's Disease? 塞利克利布(Seliciclib):库欣病的新疗法?
Pub Date : 2024-04-01 Epub Date: 2023-11-08 DOI: 10.17925/EE.2023.20.1.4
Eleni Armeni, Ashley Grossman

Previous studies have suggested that corticotroph tumours are associated with the overexpression of cyclin E and that the inactivation of cyclin-dependent kinases, which activate cyclin E, may have antisecretory and antiproliferative effects. Seliciclib, also known as R-roscovitine, is a pituitary-targeting agent shown to inhibit the growth of corticotroph tumour cells via cyclin E and retinoblastoma protein-mediated pathways. A recent study investigated the role of seliciclib in regulating biochemical parameters in a small number of patients with Cushing's disease, providing preliminary data on its possible therapeutic effectiveness in treating this disorder.

以往的研究表明,皮质营养肿瘤与细胞周期蛋白 E 的过度表达有关,而激活细胞周期蛋白 E 的细胞周期蛋白依赖性激酶失活可能具有抗分泌和抗增殖作用。Seliciclib 又称 R-roscovitine,是一种垂体靶向药物,可通过细胞周期蛋白 E 和视网膜母细胞瘤蛋白介导的途径抑制肾上腺皮质肿瘤细胞的生长。最近的一项研究调查了赛力昔单抗在调节少数库欣病患者生化指标方面的作用,为其在治疗这种疾病方面可能的疗效提供了初步数据。
{"title":"Seliciclib: A New Treatment for Cushing's Disease?","authors":"Eleni Armeni, Ashley Grossman","doi":"10.17925/EE.2023.20.1.4","DOIUrl":"10.17925/EE.2023.20.1.4","url":null,"abstract":"<p><p>Previous studies have suggested that corticotroph tumours are associated with the overexpression of cyclin E and that the inactivation of cyclin-dependent kinases, which activate cyclin E, may have antisecretory and antiproliferative effects. Seliciclib, also known as R-roscovitine, is a pituitary-targeting agent shown to inhibit the growth of corticotroph tumour cells via cyclin E and retinoblastoma protein-mediated pathways. A recent study investigated the role of seliciclib in regulating biochemical parameters in a small number of patients with Cushing's disease, providing preliminary data on its possible therapeutic effectiveness in treating this disorder.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in Risk Stratification of Solid Atypical Mixed Echogenicity Thyroid Nodules. 对实性非典型混合回声甲状腺结节进行风险分层的挑战。
Pub Date : 2024-04-01 Epub Date: 2023-11-09 DOI: 10.17925/EE.2023.20.1.2
Evana Valenzuela-Scheker, David N Bimston, Hubert Golingan, Allan Golding, R Mack Harrell

Background: To determine the prevalence and risk of malignancy (ROM) in solid atypical mixed echogenicity thyroid nodules (SAMENs) with sonographic patterns not classifiable by the 2015 American Thyroid Association Ultrasound Risk Stratification System (NC ATA). Methods: We searched our prospectively collected endocrine surgery thyroid nodule (TN) database, with particular attention to those solid nodules that were NC ATA. An algorithm assigned each into one of the five ATA risk groups per the 2015 American Thyroid Association Ultrasound Risk Stratification System (ATA USRSS). TNs that the algorithm could not assign to a risk group were deemed NC ATA and were subsequently analyzed. Additionally, we categorized this group using an algorithm based on the 2017 American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS). We were specifically interested in the characteristics that resulted in non-classification by the 2015 ATA USRSS and the fine needle aspiration biopsy (FNAB) cytology and surgical pathology results from the group. Results: We evaluated data from 5,040 nodules, of which 1,772 had surgical pathology. There were 150 solid nodules not classified by 2015 ATA USRSS, all of which demonstrated atypical features along with iso-, hetero-, hyper-and mixed echogenicity (solid atypical mixed echogenicity nodules-SAMENs). Sixty of these nodules were excised and sent for surgical pathology, while 90 were followed without surgical excision. Out of the 90 that did not undergo surgery, 82 underwent FNAB with cytologic evaluation. Of our 150 SAMENs, 40 were malignant by surgical histology and six were likely malignant by cytology (total SAMEN ROM without noninvasive follicular thyroid neoplasm with papillary-l ike nuclear features 31%). The most common sonographic pattern present in our SAMEN group consisted of an isoechoic solid component with microcalcifications (28/40-70% of all excised malignant nodules). In our excised malignant SAMENs, 50% demonstrated follicular-patterned neoplastic architecture while 48% displayed papillary architecture. Conclusion: Our study demonstrates that SAMENs with at least one suspicious sonographic feature: including (1) microcalcifications; (2) irregular or other suspicious margins,;opulation, and a higher ROM (31%) than the intermediate-risk group of the 2015 ATA USRSS (10-20%).

背景:目的:确定具有2015年美国甲状腺协会超声风险分层系统(NC ATA)无法分类的声像图模式的实性非典型混合回声甲状腺结节(SAMENs)的患病率和恶性风险(ROM)。研究方法我们搜索了前瞻性收集的内分泌手术甲状腺结节(TN)数据库,尤其关注那些属于 NC ATA 的实性结节。根据 2015 年美国甲状腺协会超声风险分层系统(ATA USRSS),一种算法将每个结节划分为五个 ATA 风险组之一。算法无法分配到风险组的 TN 被视为 NC ATA,随后进行分析。此外,我们还使用基于 2017 年美国放射学会甲状腺成像报告和数据系统(ACR-TIRADS)的算法对该组进行了分类。我们特别关注导致 2015 ATA USRSS 未分类的特征以及该组患者的细针穿刺活检 (FNAB) 细胞学和手术病理学结果。结果:我们评估了 5040 个结节的数据,其中 1772 个进行了手术病理检查。有150个实性结节未按2015 ATA USRSS分类,所有这些结节都表现出非典型特征,同时伴有等、异、高和混合回声(实性非典型混合回声结节-SAMENs)。其中 60 个结节被切除并送去做手术病理检查,90 个结节则没有做手术切除。在未进行手术的 90 个结节中,82 个进行了 FNAB 和细胞学评估。在我们的150例SAMEN中,40例经手术组织学检查为恶性,6例经细胞学检查可能为恶性(不伴有乳头状类核特征的非侵袭性滤泡性甲状腺肿瘤的SAMEN ROM总数占31%)。在我们的SAMEN组中,最常见的声像图模式是等回声实性成分伴微钙化(占所有切除恶性结节的28/40-70%)。在我们切除的恶性 SAMEN 中,50% 表现为滤泡型肿瘤结构,48% 表现为乳头状结构。结论我们的研究表明,SAMENs至少有一个可疑的声像图特征:包括(1)微钙化;(2)边缘不规则或其他可疑特征;opulation,且ROM(31%)高于2015 ATA USRSS的中危组(10-20%)。
{"title":"Challenges in Risk Stratification of Solid Atypical Mixed Echogenicity Thyroid Nodules.","authors":"Evana Valenzuela-Scheker, David N Bimston, Hubert Golingan, Allan Golding, R Mack Harrell","doi":"10.17925/EE.2023.20.1.2","DOIUrl":"10.17925/EE.2023.20.1.2","url":null,"abstract":"<p><p><b>Background</b>: To determine the prevalence and risk of malignancy (ROM) in solid atypical mixed echogenicity thyroid nodules (SAMENs) with sonographic patterns not classifiable by the 2015 American Thyroid Association Ultrasound Risk Stratification System (NC ATA). <b>Methods</b>: We searched our prospectively collected endocrine surgery thyroid nodule (TN) database, with particular attention to those solid nodules that were NC ATA. An algorithm assigned each into one of the five ATA risk groups per the 2015 American Thyroid Association Ultrasound Risk Stratification System (ATA USRSS). TNs that the algorithm could not assign to a risk group were deemed NC ATA and were subsequently analyzed. Additionally, we categorized this group using an algorithm based on the 2017 American College of Radiology Thyroid Imaging Reporting and Data System (ACR-TIRADS). We were specifically interested in the characteristics that resulted in non-classification by the 2015 ATA USRSS and the fine needle aspiration biopsy (FNAB) cytology and surgical pathology results from the group. <b>Results</b>: We evaluated data from 5,040 nodules, of which 1,772 had surgical pathology. There were 150 solid nodules not classified by 2015 ATA USRSS, all of which demonstrated atypical features along with iso-, hetero-, hyper-and mixed echogenicity (solid atypical mixed echogenicity nodules-SAMENs). Sixty of these nodules were excised and sent for surgical pathology, while 90 were followed without surgical excision. Out of the 90 that did not undergo surgery, 82 underwent FNAB with cytologic evaluation. Of our 150 SAMENs, 40 were malignant by surgical histology and six were likely malignant by cytology (total SAMEN ROM without noninvasive follicular thyroid neoplasm with papillary-l ike nuclear features 31%). The most common sonographic pattern present in our SAMEN group consisted of an isoechoic solid component with microcalcifications (28/40-70% of all excised malignant nodules). In our excised malignant SAMENs, 50% demonstrated follicular-patterned neoplastic architecture while 48% displayed papillary architecture. <b>Conclusion</b>: Our study demonstrates that SAMENs with at least one suspicious sonographic feature: including (1) microcalcifications; (2) irregular or other suspicious margins,;opulation, and a higher ROM (31%) than the intermediate-risk group of the 2015 ATA USRSS (10-20%).</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly. 口服奥曲肽胶囊治疗肢端肥大症的临床药理学。
Pub Date : 2024-04-01 Epub Date: 2024-01-22 DOI: 10.17925/EE.2024.20.1.9
Meliha Melin Uygur, Marta Villanova, Stefano Frara, Andrea Giustina

The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks of complications and comorbidities associated with the disease. First-line medical treatment is commonly represented by injectable somatostatin analogues (SRLs) after surgery. In June 2020, with the integration of Transient Permeation Enhancer® technology, oral octreotide capsules (OOCs) received regulatory approval from the US Food and Drug Administration for long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. We reviewed the clinical pharmacological data on the development and clinical use of OOCs. The pharmacokinetic and pharmacodynamic data on OOCs showed a dose-dependent increase in octreotide levels and remarkable suppression of growth hormone secretion. The efficacy and safety of OOCs were investigated in four clinical trials conducted on patients with complete or partially controlled acromegaly. The trials resulted in the maintenance of biochemical control after switching from injectable SRLs to OOCs, with a comparable side-effect profile. Moreover, the acromegaly symptoms improved in patients on OOC. The data showed a patient preference to continue in the OOC arm for the extension phase of the trials. From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide.

肢端肥大症治疗的首要目标是使生化指标恢复正常,因为这可以大大降低与该疾病相关的并发症和合并症的风险。一线药物治疗通常以手术后注射用体生长抑素类似物(SRL)为代表。2020 年 6 月,口服奥曲肽胶囊(OOCs)整合了瞬时渗透增强剂® 技术,获得了美国食品药品管理局的监管批准,用于对奥曲肽或兰瑞肽治疗有反应且耐受的肢端肥大症患者的长期维持治疗。我们回顾了有关 OOCs 开发和临床应用的临床药理数据。OOCs 的药代动力学和药效学数据显示,奥曲肽水平的升高呈剂量依赖性,生长激素分泌受到显著抑制。在对完全或部分受控的肢端肥大症患者进行的四项临床试验中,对 OOCs 的疗效和安全性进行了研究。试验结果表明,从注射用 SRLs 转为 OOCs 后,生化控制得以维持,且副作用不相上下。此外,使用 OOC 的患者的肢端肥大症症状也有所改善。数据显示,在试验的延长阶段,患者更倾向于继续服用口服OCT。从临床药理角度来看,口服奥曲肽制剂在疗效和安全性方面均优于注射奥曲肽。
{"title":"Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.","authors":"Meliha Melin Uygur, Marta Villanova, Stefano Frara, Andrea Giustina","doi":"10.17925/EE.2024.20.1.9","DOIUrl":"10.17925/EE.2024.20.1.9","url":null,"abstract":"<p><p>The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks of complications and comorbidities associated with the disease. First-line medical treatment is commonly represented by injectable somatostatin analogues (SRLs) after surgery. In June 2020, with the integration of Transient Permeation Enhancer® technology, oral octreotide capsules (OOCs) received regulatory approval from the US Food and Drug Administration for long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide. We reviewed the clinical pharmacological data on the development and clinical use of OOCs. The pharmacokinetic and pharmacodynamic data on OOCs showed a dose-dependent increase in octreotide levels and remarkable suppression of growth hormone secretion. The efficacy and safety of OOCs were investigated in four clinical trials conducted on patients with complete or partially controlled acromegaly. The trials resulted in the maintenance of biochemical control after switching from injectable SRLs to OOCs, with a comparable side-effect profile. Moreover, the acromegaly symptoms improved in patients on OOC. The data showed a patient preference to continue in the OOC arm for the extension phase of the trials. From the clinical pharmacological perspective, oral formulation of octreotide has the advantage of efficacy and safety with respect to injectable octreotide.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral Octreotide Capsules and Paltusotine in Management of Acromegaly. 口服奥曲肽胶囊和帕曲肽治疗肢端肥大症。
Pub Date : 2024-04-01 Epub Date: 2023-11-08 DOI: 10.17925/EE.2023.20.1.3
David S McLaren, Khyatisha Seejore, Julie Lynch, Robert D Murray

Injectable somatostatin receptor ligands (iSRL) are the most frequently utilized medical therapy in patients with acromegaly; however, satisfaction rates are suboptimal. Injections can result in local erythema, discomfort and subcutaneous nodule formation, encompassed with the inconvenience of attending either primary or secondary care medical facilities for injections every 4 weeks. Some patients also note breakthrough of acromegaly-related symptoms towards the end of the injection cycle. To improve acceptance and ultimately improve wellbeing of these individuals, two oral SRLs, oral octreotide capsules (OOC) and paltusotine, have been developed. The OOC combines an enteric coating to allow delivery to the small intestines and a transient permeability enhancer to enable oral bioavailability. Comparable octreotide levels are obtained with twice-daily OOC and subcutaneous octreotide 100 µg. Phase III studies show OOC to maintain equivalent biochemical control in at least 60% of patients previously receiving a stable dose of iSRL. In longer-term studies, the response to OOC was durable up to 3 years. Paltusotine is a novel potent orally available non-peptidyl somatostatin receptor subtype-2 ligand. Studies in healthy volunteers show dose-dependent suppression of growth hormone-releasing hormone-induced growth hormone secretion and suppression of insulin-like growth factor-I (IGF-I) with repeat doses. In the recent phase II study, patients with acromegaly who were partial responders (IGF-I 1.0 - 2.5 x upper limit of normal) to monotherapy with iSRL when switched to once-daily paltusotine maintained control of IGF-I within 20% of baseline or lower in 87% after 13 weeks. Adverse events with both OOC and paltusotine were reflective of those recognized with iSRL and occurred at a similar frequency. OOC and paltusotine are well-received additions to the therapeutic armamentarium in medical therapy for the management of acromegaly; however, further data on efficacy, tumour control and shrinkage are required to allow positioning of this medication within the management algorithm for acromegaly.

注射用体生长抑素受体配体(iSRL)是肢端肥大症患者最常用的药物疗法,但满意率却不尽如人意。注射会导致局部红斑、不适和皮下结节的形成,每 4 周还需前往初级或二级医疗机构进行注射,十分不便。一些患者还注意到,在注射周期即将结束时,与肢端肥大症相关的症状会有所突破。为了提高这些患者的接受度并最终改善他们的健康状况,我们开发了两种口服SRL,即口服奥曲肽胶囊(OOC)和帕妥索汀。口服奥曲肽胶囊结合了肠溶衣和瞬时渗透增强剂,前者可将奥曲肽输送到小肠,后者可提高口服生物利用度。每天两次的 OOC 和皮下注射奥曲肽 100 µg 可获得相似的奥曲肽水平。III 期研究显示,在之前接受稳定剂量 iSRL 治疗的患者中,至少有 60% 的患者使用 OOC 可维持同等的生化控制。在长期研究中,对 OOC 的反应可持续 3 年之久。Paltusotine 是一种新型强效口服非肽基体生长抑素受体亚型-2 配体。对健康志愿者的研究显示,该药对生长激素释放激素诱导的生长激素分泌和胰岛素样生长因子-I(IGF-I)的抑制与重复剂量有关。在最近的 II 期研究中,对 iSRL 单药治疗部分应答(IGF-I 为正常值上限的 1.0 - 2.5 倍)的肢端肥大症患者在改用每日一次的帕曲托汀治疗 13 周后,87% 的患者的 IGF-I 控制在基线的 20% 或更低水平。OOC和帕妥索汀的不良反应与iSRL的不良反应相似,发生频率也相似。在治疗肢端肥大症的药物疗法中,OOC和帕妥索汀是备受欢迎的新药;然而,还需要更多有关疗效、肿瘤控制和缩小的数据,才能将这种药物纳入肢端肥大症的治疗方案中。
{"title":"Oral Octreotide Capsules and Paltusotine in Management of Acromegaly.","authors":"David S McLaren, Khyatisha Seejore, Julie Lynch, Robert D Murray","doi":"10.17925/EE.2023.20.1.3","DOIUrl":"10.17925/EE.2023.20.1.3","url":null,"abstract":"<p><p>Injectable somatostatin receptor ligands (iSRL) are the most frequently utilized medical therapy in patients with acromegaly; however, satisfaction rates are suboptimal. Injections can result in local erythema, discomfort and subcutaneous nodule formation, encompassed with the inconvenience of attending either primary or secondary care medical facilities for injections every 4 weeks. Some patients also note breakthrough of acromegaly-related symptoms towards the end of the injection cycle. To improve acceptance and ultimately improve wellbeing of these individuals, two oral SRLs, oral octreotide capsules (OOC) and paltusotine, have been developed. The OOC combines an enteric coating to allow delivery to the small intestines and a transient permeability enhancer to enable oral bioavailability. Comparable octreotide levels are obtained with twice-daily OOC and subcutaneous octreotide 100 µg. Phase III studies show OOC to maintain equivalent biochemical control in at least 60% of patients previously receiving a stable dose of iSRL. In longer-term studies, the response to OOC was durable up to 3 years. Paltusotine is a novel potent orally available non-peptidyl somatostatin receptor subtype-2 ligand. Studies in healthy volunteers show dose-dependent suppression of growth hormone-releasing hormone-induced growth hormone secretion and suppression of insulin-like growth factor-I (IGF-I) with repeat doses. In the recent phase II study, patients with acromegaly who were partial responders (IGF-I 1.0 - 2.5 x upper limit of normal) to monotherapy with iSRL when switched to once-daily paltusotine maintained control of IGF-I within 20% of baseline or lower in 87% after 13 weeks. Adverse events with both OOC and paltusotine were reflective of those recognized with iSRL and occurred at a similar frequency. OOC and paltusotine are well-received additions to the therapeutic armamentarium in medical therapy for the management of acromegaly; however, further data on efficacy, tumour control and shrinkage are required to allow positioning of this medication within the management algorithm for acromegaly.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to Correct Informed Patient Consent Statement. 更正患者知情同意声明的勘误。
Pub Date : 2024-04-01 Epub Date: 2023-12-07 DOI: 10.17925/EE.2024.20.1.2
Hiya Boro, Harish Sharma, Deepak Mittal, Mohit Pareek, Shilpa Chugh, Mohar Singh Jakhar, Neeraj Nagar, Lovekesh Bhatia, Sanjay Saini, Vashishth Joshi, Sahil Vaid, Velmurugan Mannar, Lakshmi Nagendra, Mazhar Dalv, Vikash Bundela

[This corrects the article DOI: 10.17925/EE.2023.19.2.6.].

[此处更正了文章 DOI:10.17925/EE.2023.19.2.6.]。
{"title":"Erratum to Correct Informed Patient Consent Statement.","authors":"Hiya Boro, Harish Sharma, Deepak Mittal, Mohit Pareek, Shilpa Chugh, Mohar Singh Jakhar, Neeraj Nagar, Lovekesh Bhatia, Sanjay Saini, Vashishth Joshi, Sahil Vaid, Velmurugan Mannar, Lakshmi Nagendra, Mazhar Dalv, Vikash Bundela","doi":"10.17925/EE.2024.20.1.2","DOIUrl":"https://doi.org/10.17925/EE.2024.20.1.2","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.17925/EE.2023.19.2.6.].</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective. 胎盘在妊娠糖尿病中的作用:分子视角。
Pub Date : 2024-04-01 Epub Date: 2024-03-14 DOI: 10.17925/EE.2024.20.1.5
María José Calvo, Heliana Parra, Raquel Santeliz, Jordan Bautista, Eliana Luzardo, Nelson Villasmil, María Sofía Martínez, Maricamen Chacín, Clímaco Cano, Ana Checa-Ros, Luis D'Marco, Valmore Bermúdez, Juan Bautista De Sanctis

During pregnancy, women undergo several metabolic changes to guarantee an adequate supply of glucose to the foetus. These metabolic modifications develop what is known as physiological insulin resistance. When this process is altered, however, gestational diabetes mellitus (GDM) occurs. GDM is a multifactorial disease, and genetic and environmental factors play a crucial role in its aetiopathogenesis. GDM has been linked to both macroscopic and molecular alterations in placental tissues that affect placental physiology. This review summarizes the role of the placenta in the development of GDM from a molecular perspective, including hormonal and pro-inflammatory changes. Inflammation and hormonal imbalance, the characteristics dominating the GDM microenvironment, are responsible for placental changes in size and vascularity, leading to dysregulation in maternal and foetal circulations and to complications in the newborn. In conclusion, since the hormonal mechanisms operating in GDM have not been fully elucidated, more research should be done to improve the quality of life of patients with GDM and their future children.

在怀孕期间,妇女的新陈代谢会发生一些变化,以保证胎儿获得充足的葡萄糖供应。这些新陈代谢的变化形成了所谓的生理性胰岛素抵抗。然而,当这一过程发生改变时,就会出现妊娠糖尿病(GDM)。GDM 是一种多因素疾病,遗传和环境因素在其发病机制中起着至关重要的作用。GDM 与影响胎盘生理的胎盘组织的宏观和分子改变有关。本综述从分子角度总结了胎盘在 GDM 发病中的作用,包括激素和促炎症变化。炎症和激素失衡是 GDM 微环境的主要特征,是导致胎盘大小和血管变化的原因,从而导致母体和胎儿循环失调以及新生儿并发症。总之,由于 GDM 的激素作用机制尚未完全阐明,因此应开展更多的研究,以提高 GDM 患者及其未来子女的生活质量。
{"title":"The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective.","authors":"María José Calvo, Heliana Parra, Raquel Santeliz, Jordan Bautista, Eliana Luzardo, Nelson Villasmil, María Sofía Martínez, Maricamen Chacín, Clímaco Cano, Ana Checa-Ros, Luis D'Marco, Valmore Bermúdez, Juan Bautista De Sanctis","doi":"10.17925/EE.2024.20.1.5","DOIUrl":"10.17925/EE.2024.20.1.5","url":null,"abstract":"<p><p>During pregnancy, women undergo several metabolic changes to guarantee an adequate supply of glucose to the foetus. These metabolic modifications develop what is known as physiological insulin resistance. When this process is altered, however, gestational diabetes mellitus (GDM) occurs. GDM is a multifactorial disease, and genetic and environmental factors play a crucial role in its aetiopathogenesis. GDM has been linked to both macroscopic and molecular alterations in placental tissues that affect placental physiology. This review summarizes the role of the placenta in the development of GDM from a molecular perspective, including hormonal and pro-inflammatory changes. Inflammation and hormonal imbalance, the characteristics dominating the GDM microenvironment, are responsible for placental changes in size and vascularity, leading to dysregulation in maternal and foetal circulations and to complications in the newborn. In conclusion, since the hormonal mechanisms operating in GDM have not been fully elucidated, more research should be done to improve the quality of life of patients with GDM and their future children.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Panhypopituitarism in a Patient with Burkitt Lymphoma: A Diagnostic and Therapeutic Challenge. 伯基特淋巴瘤患者的泛垂体功能障碍:诊断和治疗的挑战。
Pub Date : 2024-04-01 Epub Date: 2023-12-15 DOI: 10.17925/EE.2024.20.1.11
Augusto Dextre-Espinoza, Sofía Pilar Ildefonso-Najarro, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Diana Carolina Deutz-Gómez Condori, Fiorella Beatriz Gonzales-Chiroque, Rodrigo Martín Rodríguez-Solis

Pituitary infiltration by systemic lymphoma is an exceedingly rare occurrence. Given its high mortality rate, it is crucial to recognize its clinical, biochemical and radiological features in order to provide timely intervention. We present the case of a 26-year-old male with a history of human immunodeficiency virus (HIV) infection who presented to the hospital with severe anemia, persistent fever, weight loss and diarrhea over the previous 4 months. Physical examination revealed a compromised general condition, fever, pallor, hepatomegaly and lymphadenopathy. Cervical lymph node biopsy confirmed Burkitt lymphoma (BL). During hospitalization, the patient developed polyuria, polydipsia, hypernatremia, fluid-resistant hypotension and hypoglycaemia. Corticosteroid therapy was initiated due to suspected adrenal insufficiency, resulting in clinical improvement but exacerbation of polyuria and hypernatremia. Plasma and urinary osmolarity confirmed arginine vasopressin deficiency, and assessment of anterior pituitary reserve revealed hypopituitarism, necessitating hormonal replacement therapy. Sellar magnetic resonance imaging with contrast revealed pituitary infiltration. The patient subsequently developed septic shock and died. BL accounts for approximately 10% of the cases of pituitary infiltration associated with lymphoma. Clinical presentation is heterogeneous, with panhypopituitarism often serving as the initial manifestation. Sellar magnetic resonance imaging plays a pivotal role in the differential diagnosis. Management typically entails chemotherapy, immunotherapy, radiation and hormonal replacement therapy. This case report describes a patient with BL and HIV infection who developed panhypopituitarism due to pituitary infiltration, an exceedingly rare presentation considered a medical emergency.

全身性淋巴瘤浸润垂体的情况极为罕见。鉴于其死亡率较高,识别其临床、生化和放射学特征以便及时干预至关重要。本病例是一名 26 岁男性,有人类免疫缺陷病毒(HIV)感染史,因严重贫血、持续发热、体重减轻和腹泻 4 个月来就诊。体格检查显示患者全身状况不佳、发热、面色苍白、肝肿大和淋巴结肿大。宫颈淋巴结活检证实了伯基特淋巴瘤(BL)。住院期间,患者出现多尿、多饮、高钠血症、耐液体性低血压和低血糖症。由于怀疑肾上腺功能不全,患者开始接受皮质类固醇治疗,结果临床症状有所改善,但多尿和高钠血症症状加剧。血浆和尿液渗透压证实精氨酸加压素缺乏,垂体前叶储备功能评估显示垂体功能减退,需要进行激素替代治疗。造影剂ellar磁共振成像显示垂体浸润。患者随后出现脓毒性休克并死亡。在与淋巴瘤相关的垂体浸润病例中,BL 约占 10%。临床表现多种多样,泛垂体功能障碍通常是最初的表现。ellar磁共振成像在鉴别诊断中起着关键作用。治疗方法通常包括化疗、免疫疗法、放疗和激素替代疗法。本病例报告描述了一名患有BL和HIV感染的患者因垂体浸润而出现泛垂体功能障碍,这是一种极为罕见的表现,被视为医疗急症。
{"title":"Panhypopituitarism in a Patient with Burkitt Lymphoma: A Diagnostic and Therapeutic Challenge.","authors":"Augusto Dextre-Espinoza, Sofía Pilar Ildefonso-Najarro, Marcio José Concepción-Zavaleta, Juan Eduardo Quiroz-Aldave, Diana Carolina Deutz-Gómez Condori, Fiorella Beatriz Gonzales-Chiroque, Rodrigo Martín Rodríguez-Solis","doi":"10.17925/EE.2024.20.1.11","DOIUrl":"10.17925/EE.2024.20.1.11","url":null,"abstract":"<p><p>Pituitary infiltration by systemic lymphoma is an exceedingly rare occurrence. Given its high mortality rate, it is crucial to recognize its clinical, biochemical and radiological features in order to provide timely intervention. We present the case of a 26-year-old male with a history of human immunodeficiency virus (HIV) infection who presented to the hospital with severe anemia, persistent fever, weight loss and diarrhea over the previous 4 months. Physical examination revealed a compromised general condition, fever, pallor, hepatomegaly and lymphadenopathy. Cervical lymph node biopsy confirmed Burkitt lymphoma (BL). During hospitalization, the patient developed polyuria, polydipsia, hypernatremia, fluid-resistant hypotension and hypoglycaemia. Corticosteroid therapy was initiated due to suspected adrenal insufficiency, resulting in clinical improvement but exacerbation of polyuria and hypernatremia. Plasma and urinary osmolarity confirmed arginine vasopressin deficiency, and assessment of anterior pituitary reserve revealed hypopituitarism, necessitating hormonal replacement therapy. Sellar magnetic resonance imaging with contrast revealed pituitary infiltration. The patient subsequently developed septic shock and died. BL accounts for approximately 10% of the cases of pituitary infiltration associated with lymphoma. Clinical presentation is heterogeneous, with panhypopituitarism often serving as the initial manifestation. Sellar magnetic resonance imaging plays a pivotal role in the differential diagnosis. Management typically entails chemotherapy, immunotherapy, radiation and hormonal replacement therapy. This case report describes a patient with BL and HIV infection who developed panhypopituitarism due to pituitary infiltration, an exceedingly rare presentation considered a medical emergency.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome. 奥西洛司他用于治疗库欣综合征的新型强效 11-β-羟化酶抑制剂。
Pub Date : 2024-04-01 Epub Date: 2023-12-11 DOI: 10.17925/EE.2024.20.1.8
Rosario Pivonello, Chiara Simeoli, Nicola Di Paola, Angelica Larocca, Erminio Massimo Crescenzo, Annamaria Colao

Osilodrostat is a novel potent oral steroidogenesis inhibitor with a non-steroidal chemical structure, recently approved for the treatment of adult patients with endogenous Cushing's syndrome, and Cushing's disease not cured bytab pituitary surgery or in whom pituitary surgery is not an option. Osilodrostat has been evaluated in different multicentre phase II and III clinical studies, and has shown to have notable effects, such as significant reductions in cortisol secretion, associated with significant improvement in body weight, blood pressure, glucose metabolism, lipid profile, psychological status and quality of life. The favourable safety profile, combined with the relevant efficacy, could make osilodrostat suitable as medical treatment in several phases of the Cushing's syndrome treatment journey: before surgery, as preoperative treatment, or instead of surgery, in cases where surgery is not an option or refused, as first-line treatment; after surgery, in cases of persistent or recurrent disease, as second-line treatment; after second surgery or radiotherapy following pituitary surgery as bridging treatment waiting for the definitive disease control, as third-line treatment. Further real-world clinical experience data are needed to confirm the current knowledge.

奥西洛德司他是一种新型强效口服类固醇生成抑制剂,具有非类固醇化学结构,最近被批准用于治疗内源性库欣综合征、垂体手术无法治愈或无法选择垂体手术的库欣病患者。奥西洛德司他已在不同的多中心 II 期和 III 期临床研究中进行了评估,结果表明其疗效显著,如皮质醇分泌显著减少,体重、血压、糖代谢、血脂、心理状态和生活质量均有明显改善。奥西洛德司他具有良好的安全性和相关疗效,可在库欣综合征治疗的多个阶段作为药物治疗:手术前,作为术前治疗,或在不能选择或拒绝手术的情况下替代手术,作为一线治疗;手术后,在疾病持续或复发的情况下,作为二线治疗;垂体手术后第二次手术或放疗后,作为等待疾病最终控制的过渡治疗,作为三线治疗。需要更多真实世界的临床经验数据来证实当前的知识。
{"title":"Osilodrostat: A Novel Potent Inhibitor of 11-Beta-Hydroxylase for the Treatment of Cushing's Syndrome.","authors":"Rosario Pivonello, Chiara Simeoli, Nicola Di Paola, Angelica Larocca, Erminio Massimo Crescenzo, Annamaria Colao","doi":"10.17925/EE.2024.20.1.8","DOIUrl":"10.17925/EE.2024.20.1.8","url":null,"abstract":"<p><p>Osilodrostat is a novel potent oral steroidogenesis inhibitor with a non-steroidal chemical structure, recently approved for the treatment of adult patients with endogenous Cushing's syndrome, and Cushing's disease not cured bytab pituitary surgery or in whom pituitary surgery is not an option. Osilodrostat has been evaluated in different multicentre phase II and III clinical studies, and has shown to have notable effects, such as significant reductions in cortisol secretion, associated with significant improvement in body weight, blood pressure, glucose metabolism, lipid profile, psychological status and quality of life. The favourable safety profile, combined with the relevant efficacy, could make osilodrostat suitable as medical treatment in several phases of the Cushing's syndrome treatment journey: before surgery, as preoperative treatment, or instead of surgery, in cases where surgery is not an option or refused, as first-line treatment; after surgery, in cases of persistent or recurrent disease, as second-line treatment; after second surgery or radiotherapy following pituitary surgery as bridging treatment waiting for the definitive disease control, as third-line treatment. Further real-world clinical experience data are needed to confirm the current knowledge.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes. Bexagliflozin 作为饮食和运动的辅助疗法,改善 2 型糖尿病成人的血糖控制。
Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.17925/EE.2024.20.1.6
Panagiotis Stachteas, Dimitrios Patoulias, Djordje S Popovic, Polyxeni Athanasiadou, Nikolaos Fragakis

Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality worldwide. Currently, over 10.5% of the adult population has been diagnosed with T2D, and almost 12% of total health expenditure is spent exclusively on T2D management globally. Sodium-glucose cotransporter-2 inhibitors are a relatively new class of oral antidiabetic agents that act by inhibiting renal sodium and glucose reabsorption. Except for their glucose-l owering effects, they have been associated with a more significant weight loss and blood pressure reduction and a lower risk of hypoglycaemia than other commonly prescribed antidiabetic drugs. On 20 January 2023, bexagliflozin became the fifth orally administered sodium-glucose transporter 2 inhibitor to be approved by the US Food and Drug Administration for the treatment of T2D as an adjunct therapy to diet and exercise in the USA after dapagliflozin, canagliflozin, empagliflozin and ertugliflozin. This review aims to discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D.

2 型糖尿病(T2D)是全球发病和死亡的主要原因之一。目前,超过 10.5% 的成年人被诊断患有 T2D,全球近 12% 的医疗总支出专门用于 T2D 的治疗。钠-葡萄糖共转运体-2 抑制剂是一类相对较新的口服抗糖尿病药物,通过抑制肾脏对钠和葡萄糖的重吸收发挥作用。除降糖作用外,与其他常用抗糖尿病药物相比,它们还具有更显著的减轻体重、降低血压和降低低血糖风险的作用。2023 年 1 月 20 日,bexagliflozin 成为继 dapagliflozin、canagliflozin、empagliflozin 和 ertugliflozin 之后,美国食品药品管理局批准的第五种口服钠-葡萄糖转运体 2 抑制剂,用于治疗 T2D,作为饮食和运动的辅助疗法。本综述旨在讨论有关贝沙格列净疗效和安全性的现有证据,贝沙格列净为 T2D 患者提供了另一种重要的治疗选择。
{"title":"Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes.","authors":"Panagiotis Stachteas, Dimitrios Patoulias, Djordje S Popovic, Polyxeni Athanasiadou, Nikolaos Fragakis","doi":"10.17925/EE.2024.20.1.6","DOIUrl":"10.17925/EE.2024.20.1.6","url":null,"abstract":"<p><p>Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality worldwide. Currently, over 10.5% of the adult population has been diagnosed with T2D, and almost 12% of total health expenditure is spent exclusively on T2D management globally. Sodium-glucose cotransporter-2 inhibitors are a relatively new class of oral antidiabetic agents that act by inhibiting renal sodium and glucose reabsorption. Except for their glucose-l owering effects, they have been associated with a more significant weight loss and blood pressure reduction and a lower risk of hypoglycaemia than other commonly prescribed antidiabetic drugs. On 20 January 2023, bexagliflozin became the fifth orally administered sodium-glucose transporter 2 inhibitor to be approved by the US Food and Drug Administration for the treatment of T2D as an adjunct therapy to diet and exercise in the USA after dapagliflozin, canagliflozin, empagliflozin and ertugliflozin. This review aims to discuss the current evidence on the efficacy and safety of bexagliflozin, which provides an important alternative treatment option for patients with T2D.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obesity and Oral Health: The Link Between Adipokines and Periodontitis. 肥胖与口腔健康:脂肪因子与牙周炎之间的联系
Pub Date : 2024-04-01 Epub Date: 2024-01-25 DOI: 10.17925/EE.2024.20.1.7
Ana Checa-Ros, Wei-Chung Hsueh, Belén Merck, Henry González-Torres, Valmore Bermúdez, Luis D'Marco

Periodontitis is a chronic inflammatory disease of the periodontium, or the supportive tissues around the tooth. This disease has been related to different risk factors, such as the presence of plaque and calculus, tobacco smoking, low socioeconomic status, and the immune state of the host. Importantly, the chronic inflammatory environment generated by periodontitis may lead to tooth loss and diverse systemic complications, such as cardiovascular disease, osteoarthritis and metabolic disease. Recent investigations have supported the role of obesity as a risk factor for periodontitis. Furthermore, studies have found obesity to compromise healing after periodontal therapy; however, the mechanisms underlying this association are not well understood. Proteins called 'adipokines' could be the factor linking obesity to periodontitis. Adipokines are bioactive molecules with hormonal properties and a structure similar to cytokines produced by the adipose tissue. Although adipokines have both pro-and anti-inflammatory effects, the shift towards pro-inflammatory actions occurs when the adipose tissue becomes pathological, as observe in the progression of conditions such as obesity or adiposopathy. This article reviews the role of adipokines in the pathophysiology and progression of periodontitis by focusing on their impact on inflammation and the molecular mechanisms through which adipokines contribute to the onset and development of periodontitis.

牙周炎是牙周或牙齿周围支持组织的一种慢性炎症性疾病。这种疾病与不同的风险因素有关,如牙菌斑和牙结石的存在、吸烟、社会经济地位低下以及宿主的免疫状态。重要的是,牙周炎产生的慢性炎症环境可能导致牙齿脱落和多种全身并发症,如心血管疾病、骨关节炎和代谢性疾病。最近的研究支持肥胖是牙周炎的一个风险因素。此外,研究还发现肥胖会影响牙周治疗后的愈合;然而,这种关联的机制还不十分清楚。被称为 "脂肪因子 "的蛋白质可能是肥胖与牙周炎的关联因素。脂肪因子是一种生物活性分子,具有荷尔蒙特性,结构类似于由脂肪组织产生的细胞因子。虽然脂肪因子既有促炎作用也有抗炎作用,但当脂肪组织发生病变时,脂肪因子的作用就会转向促炎作用,这一点在肥胖症或脂肪病等疾病的发展过程中可以观察到。本文回顾了脂肪因子在牙周炎的病理生理学和发展过程中的作用,重点探讨了脂肪因子对炎症的影响以及脂肪因子导致牙周炎发生和发展的分子机制。
{"title":"Obesity and Oral Health: The Link Between Adipokines and Periodontitis.","authors":"Ana Checa-Ros, Wei-Chung Hsueh, Belén Merck, Henry González-Torres, Valmore Bermúdez, Luis D'Marco","doi":"10.17925/EE.2024.20.1.7","DOIUrl":"10.17925/EE.2024.20.1.7","url":null,"abstract":"<p><p>Periodontitis is a chronic inflammatory disease of the periodontium, or the supportive tissues around the tooth. This disease has been related to different risk factors, such as the presence of plaque and calculus, tobacco smoking, low socioeconomic status, and the immune state of the host. Importantly, the chronic inflammatory environment generated by periodontitis may lead to tooth loss and diverse systemic complications, such as cardiovascular disease, osteoarthritis and metabolic disease. Recent investigations have supported the role of obesity as a risk factor for periodontitis. Furthermore, studies have found obesity to compromise healing after periodontal therapy; however, the mechanisms underlying this association are not well understood. Proteins called 'adipokines' could be the factor linking obesity to periodontitis. Adipokines are bioactive molecules with hormonal properties and a structure similar to cytokines produced by the adipose tissue. Although adipokines have both pro-and anti-inflammatory effects, the shift towards pro-inflammatory actions occurs when the adipose tissue becomes pathological, as observe in the progression of conditions such as obesity or adiposopathy. This article reviews the role of adipokines in the pathophysiology and progression of periodontitis by focusing on their impact on inflammation and the molecular mechanisms through which adipokines contribute to the onset and development of periodontitis.</p>","PeriodicalId":75231,"journal":{"name":"TouchREVIEWS in endocrinology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11132655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141177005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
TouchREVIEWS in endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1